Danantara Indonesia has stated its plan to focus on the integrated healthcare sector investments, a move that has drawn interest from Chinese pharmaceutical company Sino Biopharmaceutical Limited during the World Economic Forum (WEF) Annual Meeting 2026 in Davos (25/01).

The statement was delivered by Danantara Indonesia’s Chief Investment Officer, Pandu Patria Sjahrir, during the panel discussion Investors and the Patience Premium.

Danantara Highlights Healthcare as Key Investment Priority

Pandu said Danantara aims to invest in sectors that directly improve public welfare. He explained that healthcare is a priority to support productivity and enhance the well-being of Indonesian society.

“We want to invest in businesses that can improve the welfare of Indonesia and the Indonesian people. One of the things we want to focus on is the healthcare sector, how we improve the welfare of Indonesian society,” Pandu said.

Sovereign Wealth Fund Focuses on Broad Social Impact

Pandu added that Danantara, as a sovereign wealth fund, is closely associated with projects that create a broad social impact.

He said Danantara applies the same approach to all partners, whether family-owned companies or fund managers.

According to him, modern sovereign wealth funds aim not only for optimal returns but also for benefits to local communities.

China’s Healthcare Experience and Potential Cooperation

CEO of Sino Biopharmaceutical, Eric Tse, said he was interested in Danantara’s approach to healthcare investment. He expressed respect for the focus on public benefit.

“I would also like to comment, and I highly respect that aspect,” Eric Tse said.

Eric explained that Sino Biopharmaceutical is a conglomerate that expanded into China in 1978 and helped support the transformation of the country’s healthcare sector. At that time, hepatitis B affected around 80 million people in China.

“So we really helped develop the first generic drugs in China for various therapies to reduce the cost of original medicines, because at that time China was still a developing country and not yet wealthy,” he said.

He said Sino Biopharmaceutical grew by producing generic medicines and developing alongside China’s local pharmaceutical industry.

Eric added that Indonesia could follow a similar path, especially as it transitions toward innovative molecular drugs.

Eric also suggested adopting China’s patient care standards from the past 20 years, including a tiered hospital system.

He said Sino Biopharmaceutical would be open to participating in the development of such healthcare infrastructure.

PHOTO: FREEPIK

This article was created with AI assistance.

We make every effort to ensure the accuracy of our content, some information may be incorrect or outdated. Please let us know of any corrections at [email protected].